Specifica, Inc. and OpenEye Scientific recently announced their release of a new software they have developed to assist antibody engineers and bioinformaticians at pharmaceutical and biotechnology companies. This software identifies diverse antibody sets which will help advance the development of new therapeutics.
OpenEye’s Orion® Antibody Discovery Suite, which exclusively includes AbXtract™, is an antibody discovery module developed by Specifica. AbXtract uses proprietary artificial intelligence methods to assists in analyzing large amounts of sequence data to help find potential antibody therapeutics.
Andrew Bradbury, Co-Founder and Chief Scientific Officer of Specifica, says, “We are excited to partner with OpenEye Scientific, a company that shares our vision of enabling teams of any size to undertake large-scale antibody discovery efforts.” Specifica uses next generation sequencing and initially developed various bioinformatics tools for their in-house research. However, they soon realized that many other antibody engineers could benefit and that led to the development of AbXtract.
Orion is the only cloud-native fully integrated software-as-a-service molecular modeling platform. It accelerates the science of drug discovery by combining the unlimited storage and computational scalability of Amazon Web Services with powerful tools for data sharing, visualization and analysis.
Scientists can use the AbXtract antibody discovery module in the Orion Antibody Discovery Suite to characterize tens of millions of sequences, extract sequence- and function-based features, identify promising antibody leads, as well as share data and collaborate in real time.
To read the entire article see: OpenEye Scientific and Specifica Partner to Launch Orion® Antibody Discovery Suite incorporating AbXtract™